Alaa Halawa – Medium

Alaa Halawa

GC Therapeutics: A New Era for Plug-and-Play Cell Therapies

Cell therapies have shown remarkable effectiveness in treating a range of blood disorders and blood-related cancers, offering outsized…

Sep 19

GC Therapeutics: A New Era for Plug-and-Play Cell Therapies

Sep 19

Published in
MubadalaVentures

Metsera: Pioneering the Future of Obesity Therapeutics

For over seven years, our healthcare team has been expanding our ventures business, supporting companies that are revolutionizing…

Apr 18

Metsera: Pioneering the Future of Obesity Therapeutics

Apr 18

Published in
MubadalaVentures

Shifting the Clinical Research Paradigm

A discussion with Kent Thoelke, CEO of Paradigm, on our most recent investment in clinical trial transformation

Jan 30, 2023

Jan 30, 2023

Published in
MubadalaVentures

Our Investment in Pretzel Therapeutics: Creating a Powerhouse in the Mitochondria Field

As the “powerhouse of the cell,” mitochondria play a critical role in cell viability through a multitude of functions — from energy…

Sep 13, 2022

Our Investment in Pretzel Therapeutics: Creating a Powerhouse in the Mitochondria Field

Sep 13, 2022

Published in
MubadalaVentures

Navigating Biotech Funding Dynamics: Shifts in Public and Private Finance

Today, we are living through what many believe is the most exciting era in the biotech industry, an era characterized by an accelerated…

Jul 22, 2022

Navigating Biotech Funding Dynamics: Shifts in Public and Private Finance

Jul 22, 2022

Published in
MubadalaVentures

Healthcare Has a Data Problem. Here is How We Can Fix It.

Does access to seamless data matter in healthcare? To best answer this question, consider these two scenarios for patients with the same…

Dec 17, 2021

Dec 17, 2021

Published in
MubadalaVentures

Our Investment in Neumora: A Data Sciences-Driven Precision Approach to Treating Central Nervous…

Central nervous system (CNS) diseases, which include neurodegenerative disorders and neuropsychiatric illnesses, have placed a significant…

Oct 7, 2021

Our Investment in Neumora: A Data Sciences-Driven Precision Approach to Treating Central Nervous…

Oct 7, 2021

Published in
MubadalaVentures

Reimaging the Drug Value Chain

How EQRx is Improving Access to Life-Saving Medicines

Aug 16, 2021

Reimaging the Drug Value Chain

Aug 16, 2021

A Conversation with Chris Gibson, Co-Founder + CEO of Recursion

I sat down with Chris Gibson, Co-Founder and CEO of Recursion, off the heels of their recent IPO, to talk about his journey transforming…

Jun 8, 2021

A Conversation with Chris Gibson, Co-Founder + CEO of Recursion

Jun 8, 2021

The Future of Drug Discovery: Our Journey with Recursion Pharma

When Mubadala Capital launched its ventures platform in San Francisco three years ago, we had a simple mission: partner early with…

Sep 10, 2020

The Future of Drug Discovery: Our Journey with Recursion Pharma

Sep 10, 2020

Alaa Halawa

Alaa Halawa

Venture Capital Investor at Mubadala Capital-Ventures, based in SF. Backing companies tackling some of the toughest challenges in life sciences and healthcare.

Following

Help
Status
About
Careers
Press
Blog
Privacy
Terms
Text to speech
Teams